• Skip to primary navigation
  • Skip to main content
  • Skip to footer
  • LinkedIn
  • YouTube
  • Instagram
  • X
  • Contact Us
  • Clinical Trials
  • Careers
  • Investors
Insmed Insmed

Insmed

  • Company

    Company

    Get to know Insmed, see what drives us, and learn how we’re building a company where people come first.

    Learn about our company

    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships

    Our Global Company

    Find available career opportunities in the U.S., Japan, or Europe.

    Find Jobs

  • Patients

    Patients

    See how we collaborate with patients to shape every step of our shared journey.

    Learn about our
    commitment to patients

    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access

    Current Clinical Trials

    Learn more about our clinical trials or find a relevant trial near you.

    See if you may qualify

  • Science

    Science

    Discover the innovative science that fuels our commitment to delivering breakthroughs.

    Learn about our science

    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies

    Therapies

    Learn about our therapies

    • ARIKAYCE®
    • BRINSUPRI®
  • Responsibility

    Responsibility

    See how we’re continuing to advance science sustainably and ethically.

    Learn about our
    commitment to responsibility

    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
      • Global Healthcare Compliance
      • Policies & Disclosures

    Responsibility Report

    Our Responsibility Report reflects the culture and purpose we live by every day. We are committed to reporting annually on our progress and commitments.

    Learn more

  • Company
    • Company
    • Culture
    • What Guides Us
    • Management Team
    • Board of Directors
    • Partnerships
  • Patients
    • Patients
    • Disease Areas
    • Patient Advocacy & Resources
    • Patient Access
  • Science
    • Science
    • Pipeline
    • Areas of Innovation
      • Gene Therapy with Targeted Delivery
      • Protein Deimmunization
      • RNA End-Joining
      • Synthetic Rescue
    • Investigator-Initiated Research
    • Grants & Funding
  • Therapies
    • Therapies
    • ARIKAYCE®
      BRINSUPRI®
  • Responsibility
    • Responsibility
    • Patients we serve
    • Innovation we deliver
    • People we empower
    • Communities we strengthen
    • Planet we protect
    • Governance we uphold
    • Global Healthcare Compliance
    • Policies & Disclosures
  • Investors
  • Press Releases
  • Events & Presentations
  • Financials & Filings
    • Earnings Results
    • Annual Reports
    • SEC Filings
  • Corporate Governance
  • Responsibility Reports
  • Resources
    • Stock Information
    • Investor FAQs
    • Analyst Coverage
    • Email Alerts

Press Releases

Insmed to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, February 23, 2023

BRIDGEWATER, N.J., Feb. 9, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, February 23, 2023, to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (U.S.) or (929) 526-1599 (international) and referencing access code 397951. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 30 minutes after its completion through March 25, 2023, by dialing (866) 813-9403 (U.S.) or (+44) 204-525-0658 (international) and referencing access code 828224. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

(PRNewsfoto/Insmed Incorporated)

 

 

SOURCE Insmed Incorporated

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your email alerts.

Sign Up

Investor Presentation

View the latest Insmed Investor Presentation

Download

Footer

Insmed

LinkedIn YouTube Instagram X

Terms of Use Privacy Policy California Notice at Collection U.S. Consumer Health Data Privacy Policy Your Privacy Choices

© 2026 Insmed Incorporated. All Rights Reserved.

You are now leaving Insmed's website.

Insmed does not control, review, or endorse third-party websites, and you agree that Insmed is not responsible for the content of the website you are about to enter.